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DynaminRecent ﬁndings have implicated tight junction (TJ) protein Occludin (OCLN) as an essential factor for
hepatitis C virus (HCV) to enter human hepatocytes. To gain insights into OCLN-mediated HCV entry, we
created a panel of OCLN deletion mutants and found that without impairing OCLN's cell surface localization,
removal of the extracellular loop 2 (EL2) from OCLN abolished both its ability to mediate HIV–HCV
pseudotypes' (HCVpp) entry as well as its ability to coprecipitate HCV glycoprotein E2. Recombinant OCLN
EL2, however, failed to robustly bind soluble E2 (sE2) in pull-down assays. Subsequent studies revealed that
OCLN formed complex with Dynamin II, an important GTPase for endocytosis, in an EL2-dependent fashion.
HCVpp, as well as cell culture grown HCV (HCVcc), was sensitive to Dynamin knockdown or inhibition. We
conclude that OCLN EL2 dictates the Dynamin-dependent HCV entry. Furthermore, OCLN could function to
bridge virions to Dynamin-dependent endocytic machineries.Diseases and Microbiology,
ttsburgh, 130 DeSoto Street,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) exacts a heavy toll on global health by
causing acute and chronic hepatitis, cirrhosis, as well as hepatocellular
carcinoma. Infection of this single-stranded RNA virus is almost
exclusively restricted to human hepatocytes, a phenomenon that is at
least partially attributed to the speciﬁc viral entry into these cells.
Accumulated evidence suggests that HCV entry into a cell is a complex
multi-step process: infectious virions ﬁrst attach to cell surface via
low-afﬁnity binding and then associate with cellular receptors
including CD81 (Pileri et al., 1998) and SR-BI (Scarselli et al., 2002)
at higher afﬁnity; in the presence of tight junction (TJ) proteins
Claudin-1 (CLDN1) (Evans et al., 2007) and Occludin (OCLN) (Liu et
al., 2009; Ploss et al., 2009), bound virions undergo clathrin-mediated
endocytosis (Blanchard et al., 2006; Codran et al., 2006; Meertens et
al., 2006) and trafﬁc to endosomal compartments where the viral
envelope proteins undergo a conformational change and then fuse
with cellular membrane for entry (Hsu et al., 2003). Among the four
required cellular factors, CD81 and SR-BI are believed to mediate virus
attachment to the cell by interacting with viral glycoproteins (gps) E1and E2 (reviewed in (Bartosch and Cosset, 2006)). By contrast, the
speciﬁc roles of CLDN1 and OCLN in HCV entry remain elusive.
Similar to CLDN1, OCLN is also a four-transmembrane protein
present in the TJ of polarized cells, where it functions to regulate
paracellular permeability and to confer cell adhesiveness (Van Itallie
and Anderson, 1997). The predicted OCLN topology consists of a
66-amino acid (aa)-long N-terminus intracellular domain that does
not exist in CLDN1, two extracellular loops (EL1 and EL2) of similar
size, a short intracellular loop linking transmembrane domain 2 and 3,
and a 259-aa-long cytoplasmic tail (signiﬁcantly longer than that of
CLDN1). Both ELs of OCLN are enriched with tyrosine residues, and
more than half of the residues found in EL1 are tyrosines and glycines
(~60% in human, mouse and dog). EL2, in addition, was shown to
mediate the homophilic interaction between OCLNs expressed on two
adjacent cells (Van Itallie and Anderson, 1997; Wang et al., 2005;
Wong and Gumbiner, 1997). The distal C-terminal cytoplasmic
domain of OCLN is highly homologous to an important functional
domain in the C terminus of the ELL family of RNA polymerase II
transcription factors; this region was reported to dictate protein
targeting and endocytosis (Matter and Balda, 1998). In addition, the
C-terminus can also bind to the scaffolding proteins ZO-1, ZO-2, ZO-3;
cingulin; the membrane trafﬁcking protein VAP33; and the cytoskel-
etal protein F-actin (Feldman et al., 2005).
The observation that the OCLN ELs failed to substitute CLDN1 ELs
highlights the different roles that CLDN1 and OCLN play in mediating
HCV entry (Liu et al., 2009). We have previously shown that the
endogenous OCLN coprecipitated with HCV E2 in HCVcc-infected
Fig. 1.OCLN EL2 is essential tomediate HCVpp entry. (A) About 5×105 786-O cells were
transduced with lentiviruses to express Flag-tagged hOCLN, OCLN/ΔN, OCLN/ΔC,
OCLN/ΔEL1, and OCLN/ΔEL2. pTrip-GFP virus (expressing the green ﬂuorescent
protein) was included to control for transduction. Cell lysates were made at 48 hours
p.i. and immunoblotted with an anti-Flag antibody (top panel) or a monoclonal anti-
OCLN antibody (bottom panel). OCLN/ΔC (indicated with a star sign in top panel) could
not be recognized by the anti-OCLN antibody as this antibody was raised against the
C-terminus of OCLN. (B) All of the OCLN constructs except OCLN/ΔEL2 rendered 786-O
cells susceptible to HCVpp infection. Data are representative of at least three
independent experiments and are presented as mean±standard deviation.
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OCLN-E2 complex is derived from an intracellular pool or it represents
the interaction between HCV particles and cell surface-anchored
OCLN. In the present study, we attempt to further investigate the
interaction between OCLN and HCV glycoproteins using OCLN
deletion mutants and recombinant proteins. To our surprise, although
c-transfected OCLN and HCV E2 readily coprecipitated in a EL2-
dependent manner, the direct binding between puriﬁed OCLN ELs and
E2 was nearly undetectable when measured by in vitro pull-down
assays. Subsequently, we observed that OCLN could form complex
with Dynamin II, the large GTPase that is critical for multiple
endocytic pathways. Silencing Dynamin II by RNA interference
(RNAi) or blocking Dynamin function inhibited HCVpp and HCVcc
entry. Altogether, HCV entry appears to be Dynamin-dependent and
requires intact OCLN EL2 domain.
Results
OCLN EL2 is necessary to confer cellular susceptibility to HCVpp
To gain insights into the OCLN-mediated HCV entry, we ﬁrst
sought to determine which domain of OCLN, a four-transmembrane
protein with a relatively long C-terminus tail, is required for its
function as a HCV entry cofactor. To this end, we created a panel of
deletional constructs expressing various regions of human OCLN
(Fig. 1A). Following lentiviral transduction, all of the mutants were
expressed as N-terminal Flag-tagged proteins in 786-O cell line which
was recently shown to be deﬁcient in endogenous OCLN (Ploss et al.,
2009) (Fig. 1A). To our surprise, the N-terminus deletant (OCLN/ΔN)
was not detected well by the anti-Flag antibody (Fig. 1A, upper panel)
but could be easily identiﬁed using an OCLN monoclonal antibody
(Fig. 1A, lower panel). This observation is consistent with that in a
previous report (Bamforth et al., 1999). Notably, the expression level
of deletants was comparable to that of the full-length OCLN. Besides
the predicted ~62 kDa band (full-length OCLN), several bands with
smaller size were also noticed, which could be truncated forms of
OCLN, as a number of host enzymes reportedly cleave OCLN at
multiple sites in different cell types (Feldman et al., 2005).
Subsequent analyses revealed that overexpression of full-length
OCLN in 786-O cells signiﬁcantly increased HCVpp entry (Fig. 1B).
Importantly, removing EL2 completely abolished OCLN's ability to
mediate HCVpp entry (Fig. 1B). By contrast, deletion of N-terminal,
C-terminal cytoplasmic domain or OCLN EL1 had no impact on
OCLN-dependent HCVpp entry (Fig. 1B). We also examined the
infection of 786-O cells by VSV-G pseudotyped virus (VSV-Gpp) and
found that expressing OCLN mutants had no effect on VSV-Gpp
infection at all (Fig. 1B). Together, these results indicate that the OCLN
EL2 is speciﬁcally required for HCVpp entry.
Next, the cellular distribution of OCLN deletants was characterized
to gain clues as to whether any of the deletions impairs themembrane
targeting of OCLN. Initial attempts to image 786-O cells, however,
were unsuccessful, we therefore transfected 293T cells with GFP-
tagged OCLN deletants and found that all OCLN deletants were able to
locate to the plasma membrane, except that OCLN/ΔC also displayed
pronounced cytoplasmic retention (Fig. 2). Consistently, the GFP–
OCLN/ΔC was not as effective in rendering 786-O cells susceptible to
HCVpp as the Flag–OCLN/ΔC did (data not shown). Perhaps due to a
larger size, addition of GFP to OCLN/ΔC altered the protein folding to a
greater extent than did the Flag tag. Nevertheless, OCLN without EL2
clearly preserved the cell surface localization pattern. To validate this
part of the observation, we performed cell surface biotinylation assay
to label plasma membrane-bound Flag-tagged OCLN and deletants.
Biotinylated cell surface proteins were enriched with streptavidin-
conjugated agarose beads. Precipitated proteins were then analyzed
by Western blotting with the anti-OCLN or anti-Flag antibody. Again,
we found that all of the mutants were transported to the cell surface(Fig. 3). Collectively, the observed inability for OCLN/ΔEL2 to mediate
HCV entry was unlikely caused by failed protein targeting to cell
surface.
Fig. 2. Cellular localization of OCLN mutants. Lenti-X 293T cells expressing indicated GFP-tagged OCLN deletants were ﬁxed and imaged by laser scanning confocal microscopy.
Nuclei were stained with Draq5 (blue). Orthogonal views were presented here.
Fig. 3. OCLN deletant that abrogates HCV entry can locate to cell surface. Lenti-X 293T
cells expressing indicated Flag-tagged OCLN deletants were surface biotinylated or
mock-treated and assessed as described in Materials and Methods. All deletants were
able to reach cell surface. Lysate from mock-treated Flag-OCLN expressing cells was
included as negative control to demonstrate the speciﬁc pull-down of biotinylated
proteins.
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(Supplementary Fig. 1). A recent report described the existence of up to
eight different splicing isoforms of OCLN in normal human liver and
other tissues (Kohaar et al., 2010). Since a construct lacking both the
N–terminus and extracellular domains of OCLN reportedly exerted a
dominant negative effect on tight junction integrity (Bamforth et al.,
1999), we explored whether our OCLN deletants would have similar
effects on HCV entry in naturally permissive cell types. It was observed
that expressing these deletants in Huh7.5.1 cells did not have
appreciable effect on HCVpp entry (Supplementary Fig. 2). Hence, the
shorter formsofOCLNdonot appear to interferewith the functionof the
full-length protein as a key mediator of virus entry.
Deletion of EL2 abolished OCLN-E2 association
We have previously shown that the viral glycoprotein E2 precipi-
tated with endogenous OCLN in HCVcc-infected hepatoma cells (Liu
et al., 2009). HCV E1, however, did not appear to form complex with
OCLN (Fig. 4A). To locate the portion of OCLN that is required for its
associationwith E2,we transfected OCLNdeletional constructs together
with HCV E2 expression plasmid into 293T cells and performed
coimmunoprecipitation (Co-IP) studies. All OCLN constructs except
theEL2deletant efﬁcientlyprecipitatedwithHCVE2(Fig. 4B), indicating
that theOCLNEL2 region is essential forOCLN-E2 association. Consistent
with what we observed earlier, although the Flag-OCLN/ΔN was not
detected well using anti-Flag antibody, the OCLN monoclonal antibody
efﬁciently recognized the exogenous protein (Fig. 4B).
Analysis of E2-OCLN direct binding using recombinant proteins
Results from the above study suggest that OCLN EL2may harbor an
interacting interface with HCV glycoprotein. To test this possibility,
we generated a panel of recombinant proteins consisting of individual
Fig. 4.OCLN EL2 is important for its association with HCV E2 in co-immunoprecipitation study. (A) 293T cells were cotransfected with indicated combinations of DNA constructs. Cell
lysates were immunoprecipitated with anti-Flag M2 afﬁnity resin at 48 hours p.i. Input cell lysates and immunoprecipitates were blotted with antibodies against HCV E1, E2, OCLN,
CLDN1, as well as β-actin. Flag-OCLN co-precipitated with HCV E2 but not with E1 alone. (B) Lysates of 293T cells transfected with indicated OCLN deletant together with an
E2-expressing plasmid (CMV-E1E2, H77) were immunoprecipitated with anti-Flag afﬁnity resin. Inputs as well as immunoprecipitates were immunoblotted with indicated
antibodies. The positions of Flag-OCLN/ΔN and ΔC were marked by a star sign.
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were expressed in 293T cells and then secreted into the media, which
could be further puriﬁed through afﬁnity columns. The expressions
and secretions of represented proteins are shown in Fig. 5A.
To measure the direct binding between OCLN or CLDN1 and HCV
E2, we performed pull-down assays using puriﬁed recombinant Fc
fusion proteins and the soluble HCV E2 (sE2 aa 384–661). Strikingly,
only CD81-LEL displayed robust binding to sE2, consistent with many
previous observations (Fig. 5B). By contrast, none of other puriﬁed
proteins bound to sE2 (Fig. 5B). The same observation could be made
when the experiment was performed at pH of 5.7, suggesting that
lowering pH alone does not induce direct binding of OCLN and E2
(data not shown). Because intracellular forms of E2 (661) were found
to bind CD81 with greater afﬁnity than the extracellular forms (Flint
et al., 2000) and because it was shown that E1E2 complexes efﬁciently
bind to CD81 whereas truncated E2 is a weak binder (Cocquerel et al.,
1999, 2003), we repeated this part of the study using either
intracellularly expressed or secreted full-length E2 or E1E2 and
found the observations were reproducible (data not shown).
Together, our data do not support a robust direct binding between
OCLN and HCV glycoproteins. Rather, it appears that OCLN and E2
perhaps colocalized to an intracellular environment when coex-
pressed. In support of this notion, Benedicto et al. (2008) recently
reported that HCV envelope components alter localization of
hepatocyte TJ-associated proteins and promote OCLN retention in
the endoplasmic reticulum (ER).
OCLN associates with Dynamin II
One possible role of OCLN in virus entry is that it directly or
indirectly mediates the internalization of virions as reported in group
B coxsackieviruses (CVB) entry (Coyne et al., 2007a,b). We previouslyfound that treatment of Huh7 cells with a Dynamin inhibitor,
Dynasore, signiﬁcantly inhibited HCVpp entry (Liu et al., 2009).
Dynamins are knownGTPases that are essential for the internalization
of clathrin-coated vesicles (Praefcke and McMahon, 2004). Dynamin I
is primarily expressed in neurons, whereas Dynamin II is ubiquitously
expressed (Praefcke and McMahon, 2004). To deﬁne the role of
Dynamin in HCV entry, we expanded the study by using four different
treatment protocols and found that addition of Dynasore prior or at
the same time of virus infection suppressed HCVpp, HCVcc, as well as
VSV-Gpp entry (Fig. 6), which is known to be Dynamin-dependent in
certain cell types (Cureton et al., 2009). For HCVcc, addition of
Dynasore postinfection even had an inhibitory effect, implying
Dynamin may be important for postentry events as well. Further
experiments also demonstrated that Dynasore pretreatment as short
as 2 hours was sufﬁcient to exert its inhibitory effect (Supplementary
Fig. 3). Of note, Dynasore treatment could not completely block the
HCVpp infection, which may be either due to incomplete blockage of
Dynamin activity, or the existence of a Dynamin-independent entry
route. To validate these observations, we knocked down the
endogenous Dynamin II in Huh7.5.1 cells by short-hairpin-based
RNAi (shRNA). As shown in Fig. 7, lentivirus-mediated shRNA-
targeting Dynamin II speciﬁcally reduced the level of Dynamin II.
Consistently, HCVpp and HCVcc infection decreased by 90% in
Dynamin II knockdown cells. Reduction of endogenous Dynamin II
also lowered the VSV-Gpp entry by 50%. By contrast, infection of cells
by HIV pseudovirions bearing HTLV-1 envelop protein (HTLVpp) was
not affected. Together, these data conﬁrmed that HCV entry is a
Dynamin-dependent event.
To investigate whether OCLN associates with Dynamin II, we
coexpressed GFP–Dynamin and Flag-tagged OCLN in 293T cells.
Shown in Fig. 8A, OCLN readily precipitated with Dynamin II
(DNM2) and the dominant negative (DN) form of Dynamin II
Fig. 5. OCLN does not bind soluble HCV E2 (sE2) directly. (A) Examples of production of human Fc (hFc) fusion proteins in 293T cells using a secretion system. Fusion proteins could
be readily detected by Western blotting using an anti-human secondary antibody in either cell lysates or supernatants. Notably, the OCLN-EL1-hFc expression is relatively low. To
ensure the speciﬁc detection, a stop codon was introduced between the EL and hFc, which results in the production of proteins without hFc tag. (B) Puriﬁed Fc fusion proteins were
bound to protein G beads ﬁrst and then incubated with sE2. After wash, bound protein was eluted and immunoblotted with anti-E2 mAb, striped, and reprobed with anti-hFc. Only
the hCD81 large extracellular loop (hCD81-LEL-hFc) could bind sE2. CLDN1-EL1(E48K)-hFc harbors an E→K mutation at residue 48.
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OCLN/ΔEL2 transfected cells (Fig. 8A), but not in cells that were
transfected with OCLN/ΔEL1, ΔN, and ΔCmutants. Interestingly, Flag-
CLDN1 also precipitated with DNM2, but Flag-CD81 failed to do so.
Therefore, the interactions are unlikely due to overexpression of
recombinant proteins or to the tag added for the pull-down (Fig. 8B).
Dynamin is required for HCV entry into polarized PHHs
Because those commonly used hepatoma cell lines are phenotyp-
ically distinct from hepatocytes in vivo, we repeated the above studies
using polarized primary human hepatocytes (PHHs) to rule out the
possibility that the observation is merely cell line speciﬁc. When
seeded in collagen-coated or Matrigel-overlaid plates, PHHs can
develop into complex polarized cell monolayer, exhibiting visible bile
canaliculi between adjacent hepatocytes (Fig. 9A and Supplementary
Fig. 4). Confocal microscopic characterization of the cells revealed
polarized distribution of TJ protein CLDN1, OCLN, and the apical
surface marker, CD26 (Figs. 9B, C, and F). CD81, on the other hand,
displayed a basolateral localization pattern (Fig. 9D). The staining of
adherens junction protein, E-cadherin, was seen in lateral surface and
concentrated at AJ-like structures (Fig. 9E). Altogether, such complex
orientation of polarity is in sharp contrast to the simple (columnar)
apical–basolateral polarity observed in intestinal epithelial cells and
in other commonly used hepatoma cell lines (Brazzoli et al., 2008;
Coyne et al., 2007a; Mee et al., 2008; Yang et al., 2008a,b). Finally,
treatment of PHHs with Dynasore signiﬁcantly inhibited HCVpp entry
(Fig. 9G), conﬁrming the important role of Dynamin in virus entry. To
ensure that the inhibitory effect was not a result of Dynasore-
associated cytotoxicity, we determined the cell viability using the
CytoVial Glo system. Shown in Fig. 10, Dynasore at 80 μMdid not exertany adverse effect on Huh7.5.1 cell viability even after 24 hrs
incubation.
Discussion
Current model suggests that HCV entry into host cells is a
multistep event requiring four essential host factors including SR-BI,
CD81, CLDN1, and OCLN. The question that exactly how CLDN1 and
OCLN are involved in this stepwise entry process remains unan-
swered, despite some evidence pointing to a late step (Benedicto et
al., 2009; Evans et al., 2007). Published data from several groups
including us have indicated that a fraction of surface CLDN1 associates
with CD81 (Brazzoli et al., 2008; Harris et al., 2008, 2010; Kovalenko
et al., 2007; Yang et al., 2008a,b) in multiple cell types. Most recently,
it was reported that CLDN1 association with CD81 deﬁnes HCV entry
(Harris et al., 2010). Yet, when Flag-hCD81 and OCLN or CLDN1 were
coexpressed in 293T cells, CD81 selectively precipitated with CLDN1,
but not OCLN (Supplementary Fig. 5), implying CLDN1 and OCLN play
distinct roles in HCV entry. In the present study, we present two novel
ﬁndings with regard to the speciﬁc role of OCLN in mediating HCV
entry. First, although OCLN precipitates with HCV E2 in transfected
cells, recombinant sE2, and OCLN ELs do not bind to each other.
Second, OCLN forms complex with Dynamin, and HCV infection is
sensitive to Dynamin inhibition. These ﬁndings reminisce of CVB
entry, where CVB entry across epithelial TJ requires OCLN but OCLN
does not interact directly with the virus, and CVB-induced macro-
pinocytosis of OCLN appears to be a separate event from CVB-CAR
interaction (Coyne et al., 2007a,b).
Our study indicate that the EL2 domain plays a pivotal role in
OCLN-dependent HCV entry. Ploss et al. (2009) previously demon-
strated that OCLN EL2 harbors species-speciﬁc determinant for HCV
Fig. 6. Dynasore inhibits both HCVpp and HCVcc entry. (A) Schematic drawing of the
experimental setup. Huh7.5.1 cells were treated with Dynasore or DMSO under four
different protocols, differing in duration of the treatment and the time when added. A
series of concentrations were tested and the selected Dynasore concentration (80 μM)
was tested not to exert noticeable effect on cell growth. (B) Treated Huh7.5.1 cells were
analyzed for relative susceptibility to HCVpp, HCVcc-luc, and VSV-Gpp. All results are
expressed as percent infection to the DMSO-treated cells. Data are presented as mean±
standard deviation. ***pb0.0005, **pb0.005, *pb0.05.
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infectivity and its ability to precipitate with HCV E2. Unexpectedly,
removal of C-terminus of OCLN did not impair its ability to mediate
HCVpp infection of 786-O cells. We therefore infer that the
C-terminus-dependent protein–protein interactions are not essentialFig. 7. Silencing Dynamin II ablates HCV infection. Huh7.5.1 cells were transduced by
lentivirus carrying Dynamin II (DNM2) or a scrambled (CON) shRNA. After 48 hours
incubation, cells were infected by HCVpp, VSV-Gpp, HCVcc-Luc, and HTLVpp. Luciferase
activity was measured at 24 hours after infection. Data are presented as mean±
standard deviation. *pb0.05. (Inset) Western blot analysis of cells 48 hours after
transduction with CON or DNM2 shRNA. The speciﬁc knockdown of endogenous DNM2
by DNM2 shRNA was conﬁrmed.for HCVpp entry. It must be noted, however, that although all OCLN
deletants successfully located to plasma membrane, addition of
different tags to OCLN does seem to have subtle effects on the
topology of derived proteins. As shown in Fig. 1, Flag-tagged OCLN/
ΔN was not detected well by anti-Flag antibody, whereas GFP-tagged
OCLN/ΔC displayed pronounced cytoplasmic distribution (Fig. 2) and
was less effective in mediating HCVpp entry. Thus, it is possible that
the topology of the mutants has altered in ways that are immeasur-
able in our study. Moreover, 786-O cells do express very low levels of
endogenous OCLN (Supplementary Fig. 6), which could facilitate the
deletant's assembly to cell surface by compensating for the loss of
C-terminus in the exogenous counterpart.
Both our previous report (Liu et al., 2009) and the current study
show that OCLN precipitates with HCV E2 in infected or transfected
cells. However, the observation that individually puriﬁed Fc-tagged
OCLN ELs failed to robustly bind sE2 in the in vitro pull-down assay
disfavors a direct interaction between HCV glycoproteins and surface
OCLN. The discrepancy may reﬂect the nature of the multistep HCV
entry process. It is possible that HCV virions need to bind another
surface molecule(s) before association with junctional OCLN. None-
theless, addition of recombinant CD81 into the system failed to foster
the OCLN-E2 direct binding either (data not shown). Owing to the
relatively large size, addition of Fc to a protein may alter its
conformation. Moreover, taking EL1 or EL2 out of the context of the
full-length OCLNmay result in the loss of its native conformation. As a
result of this, recombinant proteins produced in the current study
may not possess the proper conformation required for the direct
binding. In spite of these caveats, puriﬁed Fc-tagged CD81-LEL
strongly bound to sE2 in our system, conﬁrming those previous
reports (Cocquerel et al., 2003; Flint et al., 1999). Collectively, these
results suggest that either OCLN is indirectly involved in HCV entry, or
its association with HCV particles only occurs at some point during
viral entry, which cannot be measured in the current study system.
As an integral TJ protein, OCLN was originally thought to be
necessary but later found to be dispensable for the formation of TJ
(Furuse et al., 1993; Saitou et al., 2000; Schulzke et al., 2005). The
observation that OCLN internalization is required for and accompa-
nied to CVB entry hints that OCLN may be a critical protein linking
virions to endocytic pathways (Coyne et al., 2007a,b). Indeed, TJs
comprise a network of cytoplasmic scaffolding proteins that provide
links to the cytoskeleton and to intracellular signaling molecules
(Balda and Matter, 2008; Tsukita et al., 2008). Three modes of
internalization have been reported to occur to TJ proteins: clathrin-
mediated endocytosis, caveolar-mediated pathway, and macropino-
cytosis (Bruewer et al., 2005; Capaldo and Nusrat, 2009; Fujita et al.,
2000; Ivanov et al., 2004). Notably, no known endocytic motif can be
found in OCLN. Here, we provided evidence that OCLN precipitated
with Dynamin II and blocking Dynamin activity inhibited HCV entry.
The association between Dynamin II and OCLN has been previously
reported at the blood–testis barrier in adult rat testes (Lie et al., 2006).
Interestingly, we found that the EL2 of OCLN is needed for its
association with Dynamin II. Whereas it is difﬁcult to envision how
EL2 could physically interact with Dynamin, because Dynamin II
locates to the cytoplasmic side of cell membrane and EL2 is
topologically outside of plasma membrane, perhaps the association
between Occludin and Dynamin requires the presence of a third
molecule that spans the two cellular compartments (extracellular
space, membrane/cytosol). The observation that Flag-CLDN1, but not
Flag-CD81, could also precipitated Dynamin in a Co-IP experiment
(Fig. 8B) further suggests a close association between TJ network and
Dynamin.
Dynamin is a well-known regulator of endocytosis and actin
cytoskeleton (Praefcke and McMahon, 2004). By maintaining a
balance of membrane protein endocytosis and intracellular mem-
brane trafﬁc, Dynamin II was recently shown to play an important role
in orchestrating epithelial cell polarity (Chua et al., 2009). Depletion
Fig. 8. Overexpressed OCLN precipitates with Dynamin II. (A) Flag-OCLN or deletants were cotransfected with GFP–Dynamin II (GFP–DNM2) or GFP–Dynamin II K44A (GFP–
DNM2K44A) into 293T cells. The same amounts of cell lysates were immunoprecipitated with anti-Flag afﬁnity resin and blotted for Dynamin II or Flag-tagged proteins. The positions
of Flag-OCLN/ΔN and ΔC were indicated with star signs. (B) GFP–DNM2 was cotransfected with Flag-CD81, CLDN1, OCLN, and OCLN/ΔEL1, respectively, into 293T cells.
Immunoprecipitation and immunoblotting were carried out as described in (A).
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Fig. 9. Dynasore treatment inhibits HCVpp entry into polarized primary human
hepatocytes (PHHs). (A) Phase contrast image of PHHs (48 hours after culturing on
collagen-coated plates). Bile canaliculi were visible as widened gaps between cells
(white arrows). For confocal images, cell were ﬁxed in methanol and stained for CLDN1
(B), OCLN (C), CD81 (D), E-cadherin (E-cad) (E), and CD26 (F). In (F), both OCLN and
CD26 were stained to show the relative location of TJ (OCLN, green) and apical
membrane (CD26, red). (G) Pretreatment of PHHs with Dynasore (12 hours, 80 μM)
strongly inhibited HCVpp and VSV–Gpp entry. Data are shown as mean±standard
deviation. **pb0.005, *pb0.05.
Fig. 10. Dynasore has no adverse effect on cell viability. PHHs were treated with
Dynasore (80 μM) for 0, 1, 2, 4, 16, and 24 hours. After removal of Dynasore, cells were
incubated for additional 48 hours before the CellTiterGlo cell viability assay (see
Materials and Methods). Data are shown as mean±standard deviation.
167S. Liu et al. / Virology 407 (2010) 160–170of Dynamin II, the only Dynamin in epithelial cells, prevents junctional
formation and induces abnormal actin assembly (Chua et al., 2009).
Interestingly, it was recently reported that TNF-induced OCLNendocytosis is also a Dynamin-dependent process (Marchiando
et al., 2010). Perhaps, through its association with Dynamin, OCLN
could be an important bridge between surface protein complex and
endocytic machinery, although it remains to be tested whether the
association of OCLN and Dynamin is absolutely necessary for HCV
entry. More analysis is needed to address whether surface OCLN is
physically engagedwith incoming HCV particles during the sequential
entry process and/or facilitate virus internalization.
Materials and methods
Cell lines and reagents
The human kidney epithelial cell line Lenti-X 293T was purchased
from Clontech. The human renal carcinoma cell line 786-O
(CRL-1932), human breast cancer cell line BT-549 (HTB-122), and
human colorectal adenocarcinoma cell line HT-29 (HTB-38) were
purchased from American Type Cell Culture (ATCC). The human liver
cell line Huh7 and its derivative clone Huh 7.5 were obtained from
Apath, Inc. with permission from Dr. Charles Rice (Rockefeller
University). The Huh7.5.1 line generated from a cured HCV replicon
cell line was provided by Dr. Francis Chisari (Scripps Research
Institute) (Zhong et al., 2005). All cell lines were maintained in
DMEM supplemented with 5% Penicillin and streptomycin, 1% NEAA,
and 10% fetal bovine serum (FBS) (Atlanta Biologicals). Primary
human hepatocytes (PHHs) were isolated from healthy donor livers
that were not used for liver transplantation. The detailed isolation
methods have been described previously (Strom et al., 1996) with
modiﬁcations as outlined in Komoroski et al. (2004). PHHs were
maintained in hepatocyte maintenance medium supplemented with
10−7 M insulin and dexamethasone (Lonza).
Antibodies were obtained from Dr. Jane McKeating (E2, clone
3/11), Dr. Harry Greenberg (anti-E1, A4), Zymed (anti-CLDN1, clones
2H10D10 and JAY.8; anti-OCLN, Cat. No. 71-1500), Santa Cruz (anti-
CD81, clone 5A6), BD Biosciences (anti-CD81, JS-81 clone; anti-CD26),
Cell Signaling (anti-E-cad, product no. 4065; anti-Dynamin, product
no. 2342), BD transduction (anti-OCLN, mAB), and Sigma (anti-Flag
M2 and β-actin). Secondary antibodies are purchased from Santa
Cruz, Jackson ImmunoResearch Laboratories, Inc, and Molecular
Probes (Invitrogen). The speciﬁc Dynamin inhibitor, Dynasore, was
purchased from Sigma.
DNA constructs
pTrip-eGFP and pCMV-dR8.2 were kindly provided by Dr.
Guangxia Gao (Institute of Biophysics, Chinese Academy of Sciences).
Trip-luc was constructed by replacing eGFP with the ﬁreﬂy luciferase
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luciferase was PCR-ampliﬁed from the pGL4-Luc vector (Promega)
with primers: 5′-AGAGGATCCACCGGTCGCCACCATGGAAGATGC-
CAAAAAC-3 ′ (sense) and 5 ′-ATAGCTCGAGTTAGACGTT-
GATCCTGGCGC-3′ (antisense). Flag-hCD81 and Flag-hCLDN1 were
previously constructed in the laboratory containing double Flag tags
and a calmodulin-binding peptide (results in ~5-kDa increase in size).
pTrip Flag-OCLN, pTrip Flag-OCLN/ΔN, pTrip Flag-OCLN/ΔC, pTrip
Flag-OCLN/ΔEL1, and pTrip Flag-OCLN/ΔEL2 express Flag-tagged full-
length human OCLN (hOCLN), OCLN/ΔN (deletion of aa 1–63),
OCLN/ΔC (deletion of aa 267–522), OCLN/ΔEL1 (deletion of aa
94–128), and OCLN/ΔEL2 (deletion of aa 200–238), respectively.
The full-length OCLN fragment was originally ampliﬁed from the
ViraPort human liver cDNA library (Stratagene) and cloned into a
modiﬁed Trip vector between EcoRV and XhoI sites. Truncated









OCLN-R: 5'-GACTCTCGAGCTATGTTT TCTGTCTATCATAGTCTC – 3′
For those ﬂuorescent OCLN constructs, Flag sequence was replaced
with the enhanced GFP.
Production of pseudoviral particles and HCVcc
To produce the pseudovirus, Lenti-X 293T cells were seeded 1 day
before transfection at 6×105 cells in a 6-cm plate in 4 ml of DMEM
containing 10% FBS. The next day, cells were transfected using
polyethylenimine (PEI, MW 25Kd, PolySciences, Inc.) (Rothwangl et
al., 2008) or Lipofectamine 2000 reagent (Invitrogen). HCVpp and
VSV-Gpp were packaged by transfecting with DNA mixture (0.5 ml)
comprising 2 μg of pTrip-Luc, 2 μg pCMV-dR8.2, and 2 μg of phCMV-
HCV E1E2 (a generous gift from Dr. F. Cosset, INSERM, France,
(Bartosch et al., 2003)) or 1 μg of pHEF-VSV-G (expressing VSV-G Env
protein). At 16 hours after transfection, media were replaced, and
supernatants containing HCVpp were typically harvested
36–48 hours after transfection and then ﬁltered through a 0.45-μm
syringe ﬁlter. Pseudotyped virus bearing the human T-cell leukemia
virus type I envelope protein (HTLVpp) was packaged by the two-
plasmid system consisting of 2 μg of pNL4.3-Luc-E-R- construct and
2 μg of HTLV Env (obtained from Dr. Fanning-Heidecker, NCI). In our
study, nonenveloped lentivirus particles (Bald virus) were also made
as the negative control. VSV-G pseudotyped lentiviruses carrying
shRNA against human Dynamin II (Sigma, target sequence: 5′-
AGTCCTACATCAACACGAA-3′) and the scramble shRNA (Addgene
plasmid 1864) were similarly produced. Production procedure of
HCVcc-expressing luciferase that was inserted between NS5A and
NS5B (sequence available upon request) (JFH1 strain) was described
elsewhere (Liu et al., 2009; Yang et al., 2008a,b).
HCVpp infection assay
To conduct the infection assay, Huh 7.5.1 or other cell lines were
seeded in a 48-well plate at the density of 5×104/well the day before
transduction. The next day, 200 μl of supernatant containing HCVpp or
Bald virus was added into each well in the presence of 4 μg/ml of
polybrene and further incubated for 3–6 hours followed by media
change. Approximately 36 hours after transduction, cells were lysed
in 100 μl of passive lysis buffer, and 20–50 μl of lysates was incubatedwith 50 μl of luciferase assay buffer and luciferase activity was
determined by a Veritas luminometer according to themanufacturer's
instruction (Promega luciferase assay kit). We typically obtain counts
ranging from 10,000–900,000, whereas the background signal from a
Bald virus infected sample is usually below 100.
Western blotting and immunoprecipitation
For cell lysate preparation, monolayer cells were lysed with lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40,
50 mM NaF, 1 mM Na3VO4, 5 mM β-glycerophosphate, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl ﬂuoride) supplemented with
protease inhibitor cocktail (Sigma or Pierce) on ice. The lysate was
cleared by centrifuging at 14,000×g for 20 min. Boiled samples in
2×SDS loading buffer were loaded onto a 9–12% polyacrylamide gel.
After electrophoresis, the separated proteins were transferred onto a
nitrocellulose membrane (Biorad, Hercules, CA). The resulting blots
were blocked within 10% milk for 1 hour and then incubated with the
primary antibody overnight at 4 °C. The secondary antibody used in
the immunoblot was a 1:2000 dilution of HRP-linked anti-IgG. The
ECL reagent (Amersham Biosciences, Piscataway, NJ) was used as the
substrate for detection. For immunoprecipitation-coupled Western
blotting, the cleared cell lysates were immunoprecipitated with the
anti-FLAG M2 afﬁnity resin (Sigma) and washed with lysis buffer.
Eluted samples were separated by 9–12% SDS–PAGEs and immuno-
blotted with indicated antibodies.
Production of Fc fusion proteins
To clone individual fragments, CD81 LEL (aa 116–202), CLDN1 EL1
(aa 29–81), CLDN1 EL2 (aa 139–164), CLDN6 EL1 (aa 29–81), CLDN7
EL1 (aa 29–81), OCLN EL1 (aa 92–132), and EL2 (aa 196–244), sE2 (aa
384–661 from H77 clone) were ampliﬁed by PCR using corresponding
primers and cloned in the pFuse-IL-2ss-hFc vector (Invivogen)
between EcoRV/BglII sites.
About 80% of conﬂuent 293T cells were transfectedwith 5 μg of DNA
plasmids expressing Fc fusion proteins by 10 μl of PEI (1 μg/μl) in 60-
mm plates. At 4~5 hours after transfection, media were replaced with
the serum-free 293 freestyle expression medium (Invitrogen). After an
additional 48 hours of incubation, supernatants were collected and
cleared by centrifugation at 12,000 rpm for 15 min. The supernatants
were puriﬁed through protein A afﬁnity beads and stored at−80 °C in
the presence of proteinase inhibitors (Roche) until use.
To perform in vitro pull-down assays, 12 μl of Protein G beads was
added to a 1.5-ml tube and preequilibrated in 800 μl of ice-cold
1×PBS. We then added around 200 μg of protein lysates to the beads
and placed the tube on a rotator in a cold room for 3–4 hours at a slow
speed. After incubation, the beads were spun down at 4000 rpm and
washed three times in 800 μl of ice-cold 1×PBS. Bound proteins were
eluted by boiling the beads in 35 μl of 2×SDS sample buffer and then
assayed by Western blotting.
Immunoﬂuorescence staining and confocal microscopy
Transfected Lenti-X 293T were ﬁxed in 2% paraformaldehyde
(15 min, RT) and directly imaged. For PHHs, cells were ﬁxed in ice-
cold methanol (5 min, RT), and then permeablized with 0.1% (vol./
vol.) Triton X-100 in PBS three times (PBST; 10 min, RT), blocked in
0.3% (wt./vol.) bovine serum albumin (BSA) in PBS (1 h, RT), and
subsequently incubated in PBS (1 h, RT) with appropriately diluted
primary antibodies against CLDN1 (1:80), OCLN (1:100), CD81
(1:250), CD26 (1:200), and E-cadherin (1:100). Samples were
washed in PBS and subsequently incubated with Alexa 488 or Alexa
568 secondary antibodies diluted in PBS (1:500). Samples were
mounted on a slide using a homemade Gelvatol mounting medium.
Images were captured on a Carl Zeiss Meta LSM 510 confocal
169S. Liu et al. / Virology 407 (2010) 160–170microscope (40× Plan-Neo/1.3 NA Oil) and edited by Photoshop
(Adobe). Nucleus was stained with Draq5 (Biostatus, United King-
dom). Z-stack images were acquired at 0.3 μm intervals. Orthogonal
views (XY, XZ, YZ) were presented in the ﬁgure.
Cell surface biotinylation assay
293T cells (6×106) were ﬁrst transfected with indicated OCLN
constructs. At 48 hours after transfection, cells were washed three
timeswith ice cold PBS and resuspended in PBS at a density of 25×106
cells/ml. Freshly prepared Sulfo-NHS-SS-biotin (Pierce) was added to
the cells (ﬁnal concentration 0.5 μg/ml) and allowed to incubate at
4 °C for 30 min. Cells were then washed three times with ice-cold PBS.
Then, 25 mM Tris (pH 8.0) was added in the initial wash to quench
any nonreacted biotin reagent. Following cell lysis in RIPA buffer
(50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EDTA, 2 mM Na3VO4, and Pierce protease
inhibitor cocktail), lysates were cleared by centrifugation at
13,000×g for 15 min at 4 °C. The cleared lysates were used for
immunoprecipitation using a 1:1 mixture of Streptavidin beads
(Pierce). Beads were washed three times with RIPA buffer, and
bound proteins were eluted by boiling the samples in SDS–PAGE
sample buffer and then resolved on 9% SDS–PAGE. Biotinylated
proteins were detected by anti-Flag or anti-Occludin antibodies.
Cell viability assay
PHHs (105 per well) were treated with Dynasore (80 μM) for the
indicated period of time. After removal of Dynasore, cells were incubated
for anadditional 48 hours in24-well plates. Thenumbersof viable cells in
culture were determined using the CellTiter-Glo Cell Viability Lumines-
cent Assay kit according to the manufacturer's instruction (Promega).
This luciferase-based assay system quantitatively measures the cellular
ATP level, an indicator of metabolically active cells.
Statistical analysis
Bar graphs were plotted to show mean±standard deviation (SD).
Statistical analyses were performed using SigmaPlot 10. A p value of
b0.05 in the Student's test was considered statistically signiﬁcant.
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